This Year's Highlights

• 25 Patients completed in clinical trial - device functioned as designed, clinical result and patient outcome described as superior.
• Secured $250K from BioValidation fund in June 2006 toward a $3 million raise.

Anticipated Highlights

• Close current $3.0 million round by October 2006.
• Exhibit and launch at American Society of Surgical Dermatology world conference in October 2006, Plam Desert, CA.
• Manufacturing ramp up and initial sales. Contract in place with Australian based dealer/care provider. Succesful colinical trial in Australia and full launch.

Corporate Mission

CleveX develops and sells innovative skin biopsy, closure and repair solutions that markedly improve patient outcomes and enhance practice economics for dermatology, cosmetic surgery and primary care physicians.

Our first product, the ExiClip, eliminates the tedious and time-consuming surgery and suture approach currently used by medical professionals to remove skin lesions and significantly improves patient outcomes. The technology was developed by surgeons at The Cleveland Clinic and is fully owned by CleveX. ExiClip makes earlier diagnosis of skin malignancies possible by moving the procedure forward in the patient care pathway.